{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 457129460
| IUPAC_name = (7''S'',9''S'')-9-Acetyl-9-amino-7-[(2''S'',4''S'',5''R'')-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7''H''-tetracene-5,12-dione
| image = amrubicin.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|amrubicin}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = [[Intravenous therapy|IV]]

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 110267-81-7
| ATC_prefix = L01
| ATC_suffix = DB10
| ATC_supplemental =  
| PubChem = 178149
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2299344
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 93N13LB4Z2
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08854
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1186894

<!--Chemical data-->
| chemical_formula =  
| C=25 | H=25 | N=1 | O=9 
| molecular_weight = 483.46 g/mol
| smiles = O=C2c1c(O)c5c(c(O)c1C(=O)c3ccccc23)C[C@](C(=O)C)(N)C[C@@H]5O[C@@H]4OC[C@@H](O)[C@@H](O)C4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VJZITPJGSQKZMX-XDPRQOKASA-N
}}

'''Amrubicin''' ([[International Nonproprietary Name|INN]]; previously known as '''SM-5887''') is an [[anthracycline]] used in the treatment of [[lung cancer]].<ref name="pmid1332624">{{cite journal |vauthors =Ueoka H, Ohnoshi T, Kimura I |title=[New anthracycline analogues in the treatment of lung cancer] |language=Japanese |journal=Gan to Kagaku Ryoho |volume=19 |issue=13 |pages=2146–9 |date=November 1992 |pmid=1332624 |doi= |url=}}</ref> It is marketed in Japan since 2002 by [[Sumitomo Dainippon Pharma|Sumitomo]] under the brand name '''Calsed'''.<ref name="/SUMITO17">{{cite web | author = Sumitomo Pharmaceuticals Co., Ltd. | year = 2003 | url = http://www.e-search.ne.jp/~jpr/PDF/SUMITO17.PDF | title = CALSED for Injection (English) | accessdate = 2008-08-17}} {{Dead link|date=October 2010|bot=H3llBot}}</ref>

Amrubicin acts by inhibiting [[topoisomerase II]], and has been compared in clinical trials with [[topotecan]], a Topoisomerase I inhibitor.<ref name=Celgene_Biopharmaceutical>{{cite web|author=Celgene Corporation |year=2008 |url=http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1121403&highlight |title=Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer |accessdate=2009-07-10 }}{{dead link|date=October 2016 |bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref name=Medical_News_Today>{{cite web | author = Medical News Today | year = 2007 | url = http://www.medicalnewstoday.com/articles/73140.php | title = Pharmion's Amrubicin Shows Encouraging Results Compared To Standard Of Care In Second Line Treatment Of Small Cell Lung Cancer | accessdate = 2009-07-10}}</ref>

It has also been studied for the treatment of bladder carcinoma<ref name="pmid8678519">{{cite journal |vauthors =Ohmori H, Tsushima T, Kobashi K |title=[Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma] |language=Japanese |journal=Gan to Kagaku Ryoho |volume=23 |issue=5 |pages=601–6 |date=April 1996 |pmid=8678519 |doi= |url=}}</ref> and gastric cancer.<ref name="pmid1647150">{{cite journal |vauthors =Tsushima K, Sakata Y, Munakata A |title=[A phase II study of SM-5887 for advanced gastric cancer] |language=Japanese |journal=Gan to Kagaku Ryoho |volume=18 |issue=7 |pages=1151–4 |date=June 1991 |pmid=1647150 |doi= |url=|display-authors=etal}}</ref>

Amrubicin was the first anthracycline derivative created by de novo synthesis and was first published in 1989 by scientists from Sumitomo.<ref>Hanada M. Amrubicin, Chapter 6 in Case Studies in Modern Drug Discovery and Development. Eds. Huang X and Aslanian RG.  John Wiley & Sons, 2012 {{ISBN|9780470601815}} [https://books.google.com/books?id=bLWjJoboJMIC&pg=PA106 P 106]</ref>

==References==
{{Reflist}}

{{Chemotherapeutic agents}}

[[Category:Anthracyclines]]
[[Category:Ketones]]
[[Category:Alcohols]]


{{antineoplastic-drug-stub}}